A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT02773381
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • semaglutide — DRUG
    Oral administration once-daily.
  • placebo — DRUG
    Oral administration once-daily.

Study Details

This trial is conducted in Europe. The aim of this trial is to investigate the effect of oral semaglutide compared with placebo on postprandial glucose and triglyceride metabolism, energy intake, appetite sensations and gastric emptying in subjects with Type 2 diabetes

Key Dates

Start date
Jun 2, 2016
Status verified
Dec 2020
Primary completion
Oct 19, 2018
Completion
Oct 19, 2018

Study Design

Enrollment
15 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide 3 mg, 7 mg, 14 mg
  • Placebo Comparator: Placebo

Primary Outcome Measure

Area under the serum glucose concentration-time curve [ Time Frame: At 12 weeks of treatment ]

Related Studies